Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma

NCT02478164 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT02478164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02478164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
July 13, 2015
Completion date
May 9, 2018
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma